December 18, 2024 Clinical Research/Diagn. Environ, Ag./Food & Bev Mass Spectrometry

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the routine clinical lab Clinical mass spectrometry testing offers unparalleled sensitivity and specificity, providing clinicians with additional diagnostic insights1 cobas Mass Spec solution will offer a fully automated, integrated and standardised workflow with IVDR-compliant assays Basel, 18 December 2024 – Roche (SIX: RO, ROG;... Read more

December 9, 2024 Clinical Research/Diagn.

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

Basel, 9 December 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (Poseida) (NASDAQ: PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain contingent... Read more

November 26, 2024 Clinical Research/Diagn. M&A, Partnerships

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies Roche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US... Read more

October 31, 2024 Clinical Research/Diagn. Product Launch

Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s disease related amyloid pathology with very good accuracy. In the largest worldwide clinical trial of its kind, the blood-based test showed very good accuracy in ruling out Alzheimer’s pathology in those being investigated for the disease,... Read more

September 4, 2024 Acad, Gov/Utilities Atomic Spectroscopy Clinical Research/Diagn.

Revio to Power Research in Male Infertility and Rare Disease at Münster University Hospital

MENLO PARK, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with the University Hospital of Münster, to use long-read whole genome sequencing to significantly advance male infertility and rare disease research. By deploying PacBio’s Revio HiFi sequencing system, researchers at... Read more

August 26, 2024 Clinical Research/Diagn. Lab Top-10

Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.

Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C. WASHINGTON, Aug. 26, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery,... Read more

July 17, 2024 Clinical Research/Diagn. Lab Top-10 Product Launch

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together... Read more

July 11, 2024 Atomic Spectroscopy Clinical Research/Diagn. Lab Top-10 Life Science Tools

Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Trials Across North America WALTHAM, Mass.–(BUSINESS WIRE)– To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is partnering with the National... Read more

June 19, 2024 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics

Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics WASHINGTON, June 19, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr.... Read more

June 3, 2024 Atomic Spectroscopy Clinical Research/Diagn. Lab Top-10 Mass Spectrometry

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research The Thermo Scientific™ Stellar™ mass spectrometer combines speed and sensitivity to advance precision medicine ANAHEIM, Calif.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast... Read more